Predictive Oncology Inc. Faces Potential Nasdaq Delisting On June 9, 2025, Predictive Oncology Inc. announced it received a notification from The Nasdaq Stock Market LLC regarding its failure to comply with the minimum $2.5 million stockholders' equity requirement for continued listing on the Nasdaq Capital Market. As a result, Nasdaq has moved to delist the company's securities. Predictive Oncology had previously submitted a compliance plan but was unable to meet the required standards within the 180-day extension period. The company has appealed the decision, which temporarily halts the delisting process pending a decision from Nasdaq's Hearings Panel. The panel has the authority to grant an extension of up to 180 days, but there is no guarantee that the appeal will be successful. Predictive Oncology is actively exploring all options to meet the listing requirements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.